tetano
Editor, Senior Moderator
Eur J Haematol
. 2020 Jun 16.
doi: 10.1111/ejh.13469. Online ahead of print.
Regional Outcomes of Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Hospitalised Patients With Haematological Malignancy
Stephen Booth[SUP] 1 [/SUP], John Willan[SUP] 1 2 [/SUP], Henna Wong[SUP] 1 [/SUP], Dalia Khan[SUP] 1 [/SUP], Rachel Farnell[SUP] 1 [/SUP], Alicia Hunter[SUP] 3 [/SUP], Toby Eyre[SUP] 1 [/SUP], Harley Katz[SUP] 4 [/SUP], Moez Dungarwalla[SUP] 5 [/SUP], Lucia Chen[SUP] 5 [/SUP], Joe Browning[SUP] 6 [/SUP], Paolo Polzella[SUP] 6 [/SUP], Nicola Gray[SUP] 2 [/SUP], Pratap Neelakantan[SUP] 7 [/SUP], Elissa K Dhillon, David Dutton[SUP] 8 [/SUP], Alex Sternberg[SUP] 8 [/SUP], Steven Prideaux[SUP] 8 [/SUP], Graham P Collins[SUP] 1 [/SUP], Andy Peniket[SUP] 1 [/SUP]
Affiliations
Abstract
Objectives: We sought to characterise the outcomes of patients with haematological malignancy and SARS-CoV-2 infection in hospital in our regional network of 7 hospitals.
Methods: Consecutive hospitalised patients with haematological malignancy and SARS-CoV-2 infection were identified from 01/03/2020 to 06/05/2020. Outcomes were categorised as death, resolved, or ongoing. The primary outcome was preliminary case fatality rate (pCFR), defined as the number of cases resulting in death as a proportion of all diagnosed cases. Analysis was primarily descriptive.
Results: 66 Patients were included, overall pCFR was 51.5%. Patients ≥ 70 years accounted for the majority of hospitalised cases (42, 63%) and fatalities (25, 74%). Mortality was similar between females (52%) and males (51%). Immunosuppressive or cytotoxic treatment within 3 months of the diagnosis of SARS-CoV-2 infection was associated with a significantly higher preliminary Case Fatality Rate (pCFR) of 70%, compared with 28% in those not on active treatment (P = 0.0013, 2 proportions z-test).
Conclusions: Mortality rates in patients with haematological malignancy and SARS-CoV-2 infection in hospital are high supporting measures to minimise the risk of infection in this population.
Keywords: Haematological malignancy; SARS-CoV-2.
. 2020 Jun 16.
doi: 10.1111/ejh.13469. Online ahead of print.
Regional Outcomes of Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Hospitalised Patients With Haematological Malignancy
Stephen Booth[SUP] 1 [/SUP], John Willan[SUP] 1 2 [/SUP], Henna Wong[SUP] 1 [/SUP], Dalia Khan[SUP] 1 [/SUP], Rachel Farnell[SUP] 1 [/SUP], Alicia Hunter[SUP] 3 [/SUP], Toby Eyre[SUP] 1 [/SUP], Harley Katz[SUP] 4 [/SUP], Moez Dungarwalla[SUP] 5 [/SUP], Lucia Chen[SUP] 5 [/SUP], Joe Browning[SUP] 6 [/SUP], Paolo Polzella[SUP] 6 [/SUP], Nicola Gray[SUP] 2 [/SUP], Pratap Neelakantan[SUP] 7 [/SUP], Elissa K Dhillon, David Dutton[SUP] 8 [/SUP], Alex Sternberg[SUP] 8 [/SUP], Steven Prideaux[SUP] 8 [/SUP], Graham P Collins[SUP] 1 [/SUP], Andy Peniket[SUP] 1 [/SUP]
Affiliations
- PMID: 32544294
- DOI: 10.1111/ejh.13469
Abstract
Objectives: We sought to characterise the outcomes of patients with haematological malignancy and SARS-CoV-2 infection in hospital in our regional network of 7 hospitals.
Methods: Consecutive hospitalised patients with haematological malignancy and SARS-CoV-2 infection were identified from 01/03/2020 to 06/05/2020. Outcomes were categorised as death, resolved, or ongoing. The primary outcome was preliminary case fatality rate (pCFR), defined as the number of cases resulting in death as a proportion of all diagnosed cases. Analysis was primarily descriptive.
Results: 66 Patients were included, overall pCFR was 51.5%. Patients ≥ 70 years accounted for the majority of hospitalised cases (42, 63%) and fatalities (25, 74%). Mortality was similar between females (52%) and males (51%). Immunosuppressive or cytotoxic treatment within 3 months of the diagnosis of SARS-CoV-2 infection was associated with a significantly higher preliminary Case Fatality Rate (pCFR) of 70%, compared with 28% in those not on active treatment (P = 0.0013, 2 proportions z-test).
Conclusions: Mortality rates in patients with haematological malignancy and SARS-CoV-2 infection in hospital are high supporting measures to minimise the risk of infection in this population.
Keywords: Haematological malignancy; SARS-CoV-2.